Company logo

ADTX - Aditxt, Inc.

NASDAQ -> Healthcare -> Biotechnology
Richmond, United States

ADTX price evolution
ADTX
Balance Sheet
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Current assets
Cash $8.88 $14.12 $10.57 $13.78
Short term investments
Net receivables
Inventory
Total current assets $9.93 $14.81 $11.03 $14.28
Long term investments
Property, plant & equipment $6.16 $3.22 $2.05 $1.35
Goodwill & intangible assets $0.27 $0.29 $0.32
Total noncurrent assets $5.98 $3.21 $2.06 $1.09
Total investments
Total assets $15.9 $18.02 $13.1 $15.37
Current liabilities
Accounts payable $1.21 $0.97 $0.24 $0.42
Deferred revenue
Short long term debt $3.89 $2.42 $0.98 $0.33
Total current liabilities $5.23 $3.4 $1.23 $0.76
Long term debt $4.71 $3.24 $0.86 $0.87
Total noncurrent liabilities $4.71 $3.24 $0.86 $0.87
Total debt $8.61 $5.66 $1.84 $1.19
Total liabilities $9.94 $6.65 $2.09 $1.62
Shareholders' equity
Retained earnings -$33.44 -$27.26 -$20.88 -$16.2
Other shareholder equity -$0.2 -$0.2 -$0.2
Total shareholder equity $5.96 $11.37 $11.01 $13.75
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018
Current assets
Cash $10.57 $0 $0.12
Short term investments
Net receivables
Inventory
Total current assets $11.03 $0 $0.12
Long term investments
Property, plant & equipment $2.05
Goodwill & intangible assets $0.32
Total noncurrent assets $2.06 $0.12
Total investments
Total assets $13.1 $0.12 $0.12
Current liabilities
Accounts payable $0.24 $1.85 $1.06
Deferred revenue
Short long term debt $0.98 $0.17 $0.16
Total current liabilities $1.23 $2.98 $1.65
Long term debt $0.86
Total noncurrent liabilities $0.86
Total debt $1.84 $0.17 $0.16
Total liabilities $2.09 $2.98 $1.65
Shareholders' equity
Retained earnings -$20.88 -$11.73 -$5.9
Other shareholder equity -$0.2 -$0.19
Total shareholder equity $11.01 -$2.85 -$1.54
Income Statement
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $0.93 $0.94 $0.42 $0.29
Selling, general & administrative $4.84 $5.16 $4.25 $2.46
Total operating expenses $5.78 $6.09 $4.67 $2.74
Operating income -$5.78 -$6.09 -$4.67 -$2.74
Income from continuing operations
EBIT -$6.16 -$6.36 -$4.67 -$2.74
Income tax expense
Interest expense $0.02 $0.02 $0.01
Net income
Net income -$6.18 -$6.38 -$4.68 -$2.74
Income (for common shares) -$6.18 -$6.38 -$4.68 -$2.74
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018
Revenue
Total revenue
Cost of revenue
Gross Profit
Operating activities
Research & development $0.94 $0.18 $0.53
Selling, general & administrative $7.93 $5.7 $5.08
Total operating expenses $8.87 $5.87 $5.61
Operating income -$8.87 -$5.87 -$5.61
Income from continuing operations
EBIT -$9.14 -$5.83 -$5.69
Income tax expense
Interest expense $0.01 $0 $0
Net income
Net income -$9.15 -$5.83 -$5.69
Income (for common shares) -$9.15 -$5.83 -$5.69
Cash Flow
(in millions $) 30 Jun 2021 31 Mar 2021 31 Dec 2020 30 Sep 2020
Net income -$6.18 -$6.38 -$4.68 -$2.74
Operating activities
Depreciation $0.13 $0.09 $0.01 $0
Business acquisitions & disposals
Stock-based compensation $0.77 $1.46 $1.62 $0.87
Total cash flows from operations -$5.01 -$4.05 -$3.15 -$3.67
Investing activities
Capital expenditures -$0.23 -$0.49 -$0.01
Investments
Total cash flows from investing -$0.29 -$0.49 -$0.01
Financing activities
Dividends paid
Sale and purchase of stock $3.72 $18.5
Net borrowings -$0.13 $4.37 -$0.06 -$0.72
Total cash flows from financing -$0.13 $8.08 -$0.06 $17.5
Effect of exchange rate
Change in cash and equivalents -$5.43 $3.54 -$3.21 $13.67
(in millions $) 31 Dec 2020 31 Dec 2019 31 Dec 2018
Net income -$9.15 -$5.83 -$5.69
Operating activities
Depreciation $0.02
Business acquisitions & disposals
Stock-based compensation $3.19 $4.23 $3.52
Total cash flows from operations -$7.22 -$0.46 -$0.39
Investing activities
Capital expenditures -$0.17
Investments
Total cash flows from investing -$0.17
Financing activities
Dividends paid
Sale and purchase of stock $18.5 $0.47 $0.63
Net borrowings -$0.4 $0 $0.12
Total cash flows from financing $17.89 $0.35 $0.48
Effect of exchange rate
Change in cash and equivalents $10.5 -$0.11 $0.09
Fundamentals
Market cap $26.59M
Enterprise value $26.31M
Shares outstanding 14.69M
Revenue $0.00
EBITDA -$19.70M
EBIT -$19.94M
Net Income -$19.98M
Revenue Q/Q N/A
Revenue Y/Y N/A
P/E ratio -1.33
EV/Sales N/A
EV/EBITDA -1.34
EV/EBIT -1.32
P/S ratio N/A
P/B ratio 4.31
Book/Share 0.42
Cash/Share 0.60
EPS -$1.36
ROA -128.13%
ROE -189.90%
Debt/Equity 0.19
Net debt/EBITDA -0.05
Current ratio 1.90
Quick ratio 1.90